Search

Your search keyword '"Gasparetto, Cristina"' showing total 949 results
Start Over Author "Gasparetto, Cristina"
949 results on '"Gasparetto, Cristina"'

2. Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients

Author

Gasparetto, Cristina, Schiller, Gary J, Tuchman, Sascha A, Callander, Natalie S, Baljevic, Muhamed, Lentzsch, Suzanne, Rossi, Adriana C, Kotb, Rami, White, Darrell, Bahlis, Nizar J, Chen, Christine I, Sutherland, Heather J, Madan, Sumit, LeBlanc, Richard, Sebag, Michael, Venner, Christopher P, Bensinger, William I, Biran, Noa, Ammu, Sonia, Ben-Shahar, Osnat, DeCastro, Andrew, Van Domelen, Dane, Zhou, Tianjun, Zhang, Chris, Bentur, Ohad S, Shah, Jatin, Shacham, Sharon, Kauffman, Michael, and Lipe, Brea

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Rare Diseases, Cancer, Hematology, Clinical Research, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Drug Administration Schedule, Female, Humans, Hydrazines, Male, Maximum Tolerated Dose, Middle Aged, Multiple Myeloma, Oligopeptides, Survival Analysis, Translocation, Genetic, Treatment Outcome, Triazoles, Public Health and Health Services, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

BackgroundProteasome inhibitors (PIs), including carfilzomib, potentiate the activity of selinexor, a novel, first-in-class, oral selective inhibitor of nuclear export (SINE) compound, in preclinical models of multiple myeloma (MM).MethodsThe safety, efficacy, maximum-tolerated dose (MTD) and recommended phase 2 dose (RP2D) of selinexor (80 or 100 mg) + carfilzomib (56 or 70 mg/m2) + dexamethasone (40 mg) (XKd) once weekly (QW) was evaluated in patients with relapsed refractory MM (RRMM) not refractory to carfilzomib.ResultsThirty-two patients, median prior therapies 4 (range, 1-8), were enrolled. MM was triple-class refractory in 38% of patients and 53% of patients had high-risk cytogenetics del(17p), t(4;14), t(14;16) and/or gain 1q. Common treatment-related adverse events (all/Grade 3) were thrombocytopenia 72%/47% (G3 and G4), nausea 72%/6%, anaemia 53%/19% and fatigue 53%/9%, all expected and manageable with supportive care and dose modifications. MTD and RP2D were identified as selinexor 80 mg, carfilzomib 56 mg/m2, and dexamethasone 40 mg, all QW. The overall response rate was 78% including 14 (44%) ≥ very good partial responses. Median progression-free survival was 15 months.ConclusionsWeekly XKd is highly effective and well-tolerated. These data support further investigation of XKd in patients with MM.

Published
2022

4. The Effect of Age and Other Patient Characteristics on Outcomes Among Nontransplanted Patients Who Were Treated With First-Line Lenalidomide, Bortezomib, and Dexamethasone: Results From the ConnectⓇ MM Registry

Author

Abonour, Rafat, Lee, Hans C., Rifkin, Robert, Ailawadhi, Sikander, Omel, James, Hardin, James W., Narang, Mohit, Toomey, Kathleen, Gasparetto, Cristina, Wagner, Lynne I., Terebelo, Howard, Mouro, Jorge, Dhanasiri, Sujith, Liu, Liang, Yu, Edward, and Jagannath, Sundar

Published
2024
Full Text
View/download PDF

6. Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials.

Author

Gavriatopoulou, Maria, Chari, Ajai, Chen, Christine, Bahlis, Nizar, Vogl, Dan, Jakubowiak, Andrzej, Dingli, David, Cornell, Robert, Hofmeister, Craig, Siegel, David, Berdeja, Jesus, Reece, Donna, White, Darrell, Lentzsch, Suzanne, Gasparetto, Cristina, Huff, Carol, Jagannath, Sundar, Baz, Rachid, Nooka, Ajay, Richter, Joshua, Abonour, Rafat, Parker, Terri, Yee, Andrew, Moreau, Philippe, Lonial, Sagar, Tuchman, Sascha, Weisel, Katja, Mohty, Mohamad, Choquet, Sylvain, Unger, T, Li, Kai, Chai, Yi, Li, Lingling, Shah, Jatin, Shacham, Sharon, Kauffman, Michael, and Dimopoulos, Meletios

Subjects
Aged, Antineoplastic Agents, Appetite, Clinical Trials as Topic, Diarrhea, Fatigue, Female, Humans, Hydrazines, Hyponatremia, Male, Middle Aged, Multiple Myeloma, Nausea, Thrombocytopenia, Triazoles
Abstract

Selinexor is an oral, small molecule inhibitor of the nuclear export protein exportin 1 with demonstrated activity in hematologic and solid malignancies. Side effects associated with selinexor include nausea, vomiting, fatigue, diarrhea, decreased appetite, weight loss, thrombocytopenia, neutropenia, and hyponatremia. We reviewed 437 patients with multiple myeloma treated with selinexor and assessed the kinetics of adverse events and impact of supportive care measures. Selinexor reduced both platelets and neutrophils over the first cycle of treatment and reached a nadir between 28 and 42 days. Platelet transfusions and thrombopoietin receptor agonists were effective at treating thrombocytopenia, and granulocyte colony stimulating factors were effective at resolving neutropenia. The onset of gastrointestinal side effects (nausea, vomiting, and diarrhea) was most common during the first 1-2 weeks of treatment. Nausea could be mitigated with 5-HT3 antagonists and either neurokinin 1 receptor antagonists, olanzapine, or cannbainoids. Loperamide and bismuth subsalicylate ameliorated diarrhea. The primary constitutional side effects of fatigue and decreased appetite could be managed with methylphenidate, megestrol, cannabinoids or olanzapine, respectively. Hyponatremia was highly responsive to sodium replacement. Selinexor has well-established adverse effects that mainly occur within the first 8 weeks of treatment, are reversible, and respond to supportive care.

Published
2020

7. Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma.

Author

Chari, Ajai, Cornell, Robert, Gasparetto, Cristina, Karanes, Chatchada, Matous, Jeffrey, Niesvizky, Ruben, Lunning, Matthew, Usmani, Saad, Anderson, Larry, Chhabra, Saurabh, Girnius, Saulius, Shustik, Chaim, Stuart, Robert, Lee, Yihua, Salman, Zeena, Liu, Emily, and Valent, Jason

Subjects
Brutons tyrosine kinase inhibitor, carfilzomib, ibrutinib, multiple myeloma, Adenine, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Drug Resistance, Neoplasm, Female, Follow-Up Studies, Humans, Male, Middle Aged, Multiple Myeloma, Neoplasm Recurrence, Local, Oligopeptides, Piperidines, Prognosis, Pyrazoles, Pyrimidines, Salvage Therapy, Survival Rate
Abstract

Patients with multiple myeloma (MM) inevitably relapse on initial treatment regimens, and novel combination therapies are needed. Ibrutinib is a first-in-class, once-daily inhibitor of Brutons tyrosine kinase, an enzyme implicated in growth and survival of MM cells. Preclinical data suggest supra-additivity or synergy between ibrutinib and proteasome inhibitors (PIs) against MM. This phase 1/2b study evaluated the efficacy and safety of ibrutinib plus the PI carfilzomib and dexamethasone in patients with relapsed/refractory MM (RRMM). In this final analysis, we report results in patients who received the recommended phase 2 dose (RP2D; ibrutinib 840 mg and carfilzomib 36 mg/m2 with dexamethasone), which was determined in phase 1. The primary efficacy endpoint was overall response rate (ORR). Fifty-nine patients with RRMM received the RP2D (18 in phase 1 and 41 in phase 2b). These patients had received a median of three prior lines of therapy; 69% were refractory to bortezomib, and 90% were refractory to their last treatment. ORR in the RP2D population was 71% (stringent complete response and complete response: 3% each). Median duration of clinical benefit and median duration of response were both 6.5 months. Median progression-free survival (PFS) was 7.4 months, and median overall survival (OS) was 35.9 months. High-risk patients had comparable ORR and median PFS (67% and 7.7 months, respectively) to non-high-risk patients, whose ORR was 73% and median PFS was 6.9 months, whereas median OS in high-risk patients was 13.9 months and not reached in non-high-risk patients. The most common grade ≥3 hematologic treatment-emergent adverse events (TEAEs) were anemia and thrombocytopenia (17% each); the most common grade ≥3 non-hematologic TEAE was hypertension (19%). In patients with RRMM treated with multiple previous lines of therapy, ibrutinib plus carfilzomib demonstrated anticancer activity within the expected efficacy range. No new safety signals were identified and the combination was well-tolerated.

Published
2020

8. Treatment Patterns, Survival, Quality of Life, and Healthcare Resource Use Among Patients With Triple-Class Refractory Multiple Myeloma in US Clinical Practice: Findings From the Connect MM Disease Registry

Author

Lee, Hans C., Ramasamy, Karthik, Weisel, Katja, Abonour, Rafat, Hardin, James W., Rifkin, Robert M., Ailawadhi, Sikander, Terebelo, Howard R., Durie, Brian G.M., Tang, Derek, Joshi, Prashant, Liu, Liang, Jou, Ying-Ming, Che, Min, Hernandez, Gabriela, Narang, Mohit, Toomey, Kathleen, Gasparetto, Cristina, Wagner, Lynne I., and Jagannath, Sundar

Published
2023
Full Text
View/download PDF

9. Selinexor-Based Triplet Regimens in Patients With Multiple Myeloma Previously Treated With Anti-CD38 Monoclonal Antibodies

Author

Schiller, Gary J., Lipe, Brea C., Bahlis, Nizar J., Tuchman, Sascha A., Bensinger, William I., Sutherland, Heather J., Lentzsch, Suzanne, Baljevic, Muhamed, White, Darrell, Kotb, Rami, Chen, Christine I., Rossi, Adriana, Biran, Noa, LeBlanc, Richard, Grosicki, Sebastian, Martelli, Maurizio, Gunsilius, Eberhard, Špička, Ivan, Stevens, Don Ambrose, Facon, Thierry, Mesa, Mercedes Gironella, Zhang, Chris, Van Domelen, Dane R., Bentur, Ohad S., and Gasparetto, Cristina

Published
2023
Full Text
View/download PDF

10. Timing of allogeneic hematopoietic cell transplantation for myelofibrosis and other myeloproliferative neoplasms.

Author

Mercer, Joshua S., primary, Bradbury, Claire I., additional, Thomas, Samantha M., additional, Ramalingam, Sendhilnathan, additional, Gasparetto, Cristina, additional, Choi, Taewoong, additional, Sung, Anthony D., additional, Sarantopoulos, Stefanie, additional, Long, Gwynn Douglas, additional, Alyea, Edwin, additional, Horwitz, Mitchell E., additional, Chao, Nelson Jen An, additional, and Hong, Sanghee, additional

Published
2024
Full Text
View/download PDF

11. Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma

Author

Gopalakrishnan, Sathish, D'Souza, Anita, Scott, Emma, Fraser, Raphael, Davila, Omar, Shah, Nina, Gale, Robert Peter, Kamble, Rammurti, Diaz, Miguel Angel, Lazarus, Hillard M, Savani, Bipin N, Hildebrandt, Gerhard C, Solh, Melhem, Freytes, Cesar O, Lee, Cindy, Kyle, Robert A, Usmani, Saad Z, Ganguly, Siddhartha, Assal, Amer, Berdeja, Jesus, Kanate, Abraham S, Dhakal, Binod, Meehan, Kenneth, Kindwall-Keller, Tamila, Saad, Ayman, Locke, Frederick, Seo, Sachiko, Nishihori, Taiga, Gergis, Usama, Gasparetto, Cristina, Mark, Tomer, Nieto, Yago, Kumar, Shaji, and Hari, Parameswaran

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Rare Diseases, Hematology, Cancer, Transplantation, Adult, Aged, Female, Hematopoietic Stem Cell Transplantation, Humans, Male, Middle Aged, Multiple Myeloma, Neoplasm Staging, Prognosis, Recurrence, Transplantation Conditioning, Transplantation, Autologous, Myeloma stage, Postrelapse survival, Transplant, Clinical Sciences, Immunology, Cardiovascular medicine and haematology
Abstract

The revised International Staging System (R-ISS) combines ISS with genetic markers and lactate dehydrogenase and can prognosticate newly diagnosed multiple myeloma (MM). Early relapse (

Published
2019

12. Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial

Author

Stadtmauer, Edward A, Pasquini, Marcelo C, Blackwell, Beth, Hari, Parameswaran, Bashey, Asad, Devine, Steven, Efebera, Yvonne, Ganguly, Siddharta, Gasparetto, Cristina, Geller, Nancy, Horowitz, Mary M, Koreth, John, Knust, Kristin, Landau, Heather, Brunstein, Claudio, McCarthy, Philip, Nelson, Courtney, Qazilbash, Muzaffar H, Shah, Nina, Vesole, David H, Vij, Ravi, Vogl, Dan T, Giralt, Sergio, Somlo, George, and Krishnan, Amrita

Subjects
Cancer, Clinical Trials and Supportive Activities, Hematology, Clinical Research, Rare Diseases, Transplantation, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Good Health and Well Being, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Bortezomib, Consolidation Chemotherapy, Dexamethasone, Disease Progression, Female, Hematopoietic Stem Cell Transplantation, Humans, Lenalidomide, Maintenance Chemotherapy, Male, Melphalan, Middle Aged, Multiple Myeloma, Myeloablative Agonists, Progression-Free Survival, Prospective Studies, Remission Induction, Reoperation, Time Factors, Transplantation, Autologous, United States, Young Adult, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeSingle-cycle melphalan 200 mg/m2 and autologous hematopoietic cell transplantation (AHCT) followed by lenalidomide (len) maintenance have improved progression-free survival (PFS) and overall survival (OS) for transplantation-eligible patients with multiple myeloma (MM). We designed a prospective, randomized, phase III study to test additional interventions to improve PFS by comparing AHCT, tandem AHCT (AHCT/AHCT), and AHCT and four subsequent cycles of len, bortezomib, and dexamethasone (RVD; AHCT + RVD), all followed by len until disease progression.Patients and methodsPatients with symptomatic MM within 12 months from starting therapy and without progression who were age 70 years or younger were randomly assigned to AHCT/AHCT + len (n = 247), AHCT + RVD + len (n = 254), or AHCT + len (n = 257). The primary end point was 38-month PFS.ResultsThe study population had a median age of 56 years (range, 20 to 70 years); 24% of patients had high-risk MM, 73% had a triple-drug regimen as initial therapy, and 18% were in complete response at enrollment. The 38-month PFS rate was 58.5% (95% CI, 51.7% to 64.6%) for AHCT/AHCT + len, 57.8% (95% CI, 51.4% to 63.7%) for AHCT + RVD + len, and 53.9% (95% CI, 47.4% to 60%) for AHCT + len. For AHCT/AHCT + len, AHCT + RVD + len, and AHCT + len, the OS rates were 81.8% (95% CI, 76.2% to 86.2%), 85.4% (95% CI, 80.4% to 89.3%), and 83.7% (95% CI, 78.4% to 87.8%), respectively, and the complete response rates at 1 year were 50.5% (n = 192), 58.4% (n = 209), and 47.1% (n = 208), respectively. Toxicity profiles and development of second primary malignancies were similar across treatment arms.ConclusionSecond AHCT or RVD consolidation as post-AHCT interventions for the up-front treatment of transplantation-eligible patients with MM did not improve PFS or OS. Single AHCT and len should remain as the standard approach for this population.

Published
2019

15. Acceptance and Commitment Therapy May Improve Physical Function after Allogeneic Hematopoietic Stem Cell Transplant

Author

Infield, Jordan, primary, Smith, Patrick J, additional, Merwin, Rhonda M, additional, Racioppi, Alessandro, additional, O'Connell, Christine, additional, Taylor, Allison O., additional, Hill, Lauren, additional, Winthrop, Hilary, additional, Alyea, Edwin P, additional, Chao, Nelson J., additional, Choi, Taewoong, additional, Gasparetto, Cristina, additional, Hong, Sanghee, additional, Horwitz, Mitchell, additional, Kang, Yubin, additional, Long, Gwynn D, additional, Lopez, Richard D, additional, Ramalingam, Sendhilnathan, additional, Sarantopoulos, Stefanie, additional, and Sung, Anthony D, additional

Published
2024
Full Text
View/download PDF

18. Clinical and Neuroimaging Correlates of Post-Transplant Delirium

Author

Smith, Patrick, Thompson, Jillian C., Perea, Elena, Wasserman, Brian, Bohannon, Lauren, Racioppi, Alessandro, Choi, Taewoong, Gasparetto, Cristina, Horwitz, Mitchell E., Long, Gwynn, Lopez, Richard, Rizzieri, David A., Sarantopoulos, Stefanie, Sullivan, Keith M., Chao, Nelson J., and Sung, Anthony D.

Published
2020
Full Text
View/download PDF

19. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial

Author

Kumar, Shaji K, Harrison, Simon J, Cavo, Michele, de la Rubia, Javier, Popat, Rakesh, Gasparetto, Cristina, Hungria, Vania, Salwender, Hans, Suzuki, Kenshi, Kim, Inho, Punnoose, Elizabeth A, Hong, Wan-Jen, Freise, Kevin J, Yang, Xiaoqing, Sood, Anjla, Jalaluddin, Muhammad, Ross, Jeremy A, Ward, James E, Maciag, Paulo C, and Moreau, Philippe

Published
2020
Full Text
View/download PDF

21. Financial Toxicity and Quality of Life in Patients Undergoing Stem-Cell Transplant Evaluation: A Single-Center Analysis

Author

Hussaini, S.M. Qasim, primary, Ren, Yi, additional, Racioppi, Alessandro, additional, Lew, Meagan V., additional, Bohannon, Lauren, additional, Johnson, Ernaya, additional, Li, Yan, additional, Thompson, Jillian C., additional, Henshall, Bethany, additional, Darby, Maurisa, additional, Choi, Taewoong, additional, Lopez, Richard D., additional, Sarantopoulos, Stefanie, additional, Gasparetto, Cristina, additional, Long, Gwynn D., additional, Horwitz, Mitchell E., additional, Chao, Nelson J., additional, Zafar, S. Yousuf, additional, and Sung, Anthony D., additional

Published
2023
Full Text
View/download PDF

22. A Multicenter Phase II, Double-Blind, Placebo-Controlled Trial of Maintenance Ixazomib After Allogeneic Transplantation for High-Risk Multiple Myeloma: Results of the Blood and Marrow Transplant Clinical Trials Network 1302 Trial

Author

Bashir, Qaiser, Nishihori, Taiga, Pasquini, Marcelo C., Martens, Michael J., Wu, Juan, Alsina, Melissa, Anasetti, Claudio, Brunstein, Claudio, Dawson, Peter, Efebera, Yvonne, Gasparetto, Cristina, Geller, Nancy, Giralt, Sergio, Hall, Aric C., Koreth, John, McCarthy, Philip, Scott, Emma, Stadtmauer, Edward A., Vesole, David H., and Hari, Parameswaran

Published
2023
Full Text
View/download PDF

23. A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma

Author

Mikhael, Joseph, Richter, Joshua, Vij, Ravi, Cole, Craig, Zonder, Jeffrey, Kaufman, Jonathan L., Bensinger, William, Dimopoulos, Meletios, Lendvai, Nikoletta, Hari, Parameswaran, Ocio, Enrique M., Gasparetto, Cristina, Kumar, Shaji, Oprea, Corina, Chiron, Marielle, Brillac, Claire, Charpentier, Eric, San-Miguel, Jesús, and Martin, Thomas

Published
2020
Full Text
View/download PDF

24. A Phase I Trial of SYK Inhibition with Fostamatinib in the Prevention and Treatment of Chronic Graft-Versus-Host Disease

Author

Lin, Chenyu, DiCioccio, Rachel A., Haykal, Tarek, McManigle, William C., Li, Zhiguo, Anand, Sarah M., Poe, Jonathan C., Bracken, Sonali J., Jia, Wei, Alyea, Edwin P., III, Cardones, Adela R., Choi, Taewoong, Gasparetto, Cristina, Grunwald, Michael R., Hennig, Therese, Kang, Yubin, Long, Gwynn D., Lopez, Richard, Martin, Melissa, Minor, Kerry K., Quinones, Victor L. Perez, Sung, Anthony D., Wiggins, Kristi, Chao, Nelson J., Horwitz, Mitchell E., Rizzieri, David A., and Sarantopoulos, Stefanie

Published
2023
Full Text
View/download PDF

26. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

Author

Nicol, Andrew, Grigoriadis, George, Catalano, John, LeBlanc, Richard, Elemary, Mohamed, Bahlis, Nizar, Facon, Thierry, Karlin, Lionel, Ribrag, Vincent, Attal, Michel, Goldschmidt, Hartmut, Engelhardt, Monika, Weisel, Katja, Mackensen, Andreas, Nagler, Arnon, Ben Yehuda, Dina, Avivi, Irit, Benyamini, Noam, Magen-Nativ, Hila, Palumbo, Antonio, Cavo, Michele, Tobinai, Kensei, Iida, Shinsuke, Chou, Takaai, Suzuki, Kenshi, Kosugi, Hiroshi, Taniwaki, Masafumi, Sunami, Kazutaka, Matsumoto, Morio, Ando, Kiyoshi, Ganly, Peter, Blacklock, Hilary, Simpson, David, George, Anupkumar, Schjesvold, Fredrik, Gjertsen, Bjorn, Lahuerta, Juan, Blade, Joan, Oriol Rocafiguera, Albert, Mateos, Maria, Rodriguez-Otero, Paula, Larson, Sarah, Atanackovic, Djordje, Devarakonda, Srinivas, Bitran, Jacob, Zonder, Jeffrey, Morganstein, Neil, Hay, Mohammad, Chanan-Khan, Asher, Saylors, Gene, Kio, Ebenezer, Oliff, Ira, Kirkel, Dean, Shtivelband, Mikhail, Yuen, Carrie, Yee, Andrew, Shah, Jatin, Htut, Myo, Raza, Shahzad, Chhabra, Saurabh, Stiff, Patrick, Hari, Parameswaran, Bank, Bruce, Malek, Ehsan, Gasparetto, Cristina, Faroun, Ycaoub, Sherbenou, Daniel, Kreisle, William, Singhal, Seema, Rosenblatt, Jacalyn, Usmani, Saad, Lee, Wes, Safah, Hana, Lutzky, Jose, Suh, Jason, Pan, Dorothy, Baron, Ari, Manges, Robert, Steis, Ronald, Oliveira, Moacyr, Moreb, Jan, Callander, Natalie, Anz, Bertrand, Raptis, Anastasios, Stampleman, Laura, Melear, Jason, Boyd, Thomas, Garbo, Lawrence, Klein, Leonard, Shao, Spencer, Lyons, Roger, McIntyre, Kristi, Tarantolo, Stefano, Yasenchak, Christopher, Yimer, Habte, Mateos, Maria-Victoria, Oriol, Albert, Larocca, Alessandra, Usmani, Saad Z, Jagannath, Sundar, Ocio, Enrique M, San Miguel, Jesus, Kher, Uma, Farooqui, Mohammed, Liao, Jason, Marinello, Patricia, and Lonial, Sagar

Published
2019
Full Text
View/download PDF

27. A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab

Author

Mikhael, Joseph, Belhadj-Merzoug, Karim, Hulin, Cyrille, Vincent, Laure, Moreau, Philippe, Gasparetto, Cristina, Pour, Ludek, Spicka, Ivan, Vij, Ravi, Zonder, Jeffrey, Atanackovic, Djordje, Gabrail, Nashat, Martin, Thomas G., Perrot, Aurore, Bensfia, Samira, Weng, Qilong, Brillac, Claire, Semiond, Dorothée, Macé, Sandrine, Corzo, Kathryn P., and Leleu, Xavier

Published
2021
Full Text
View/download PDF

30. P-285 Real-world clinical outcomes and treatment patterns among patients with triple-class exposed multiple myeloma: an analysis using the Connectmultiple myeloma disease registry

Author

Lee, Hans, primary, Ailawadhi, Sikander, additional, Dhanda, Devender, additional, Patwardhan, Pallavi, additional, Yu, Edward, additional, Liu, Liang, additional, Rifkin, Robert, additional, Terebelo, Howard, additional, Abonour, Rafat, additional, Narang, Mohit, additional, Gasparetto, Cristina, additional, Toomey, Kathleen, additional, Hardin, James, additional, Durie, Brian, additional, and Jagannath, Sundar, additional

Published
2023
Full Text
View/download PDF

31. OA-29 First results from the randomized portion of a phase 2 study of venetoclax plus carfilzomib-dexamethasone vs carfilzomib-dexamethasone in patients with t(11;14) relapsed/refractory multiple myeloma

Author

Kaufman, Jonathan, primary, Gasparetto, Cristina, additional, Kovacsovics, Tibor, additional, Mikala, Gabor, additional, Masszi, Tamas, additional, Rosinol, Laura, additional, Janowski, Wojciech, additional, Oriol, Albert, additional, Onishi, Maika, additional, Liu, Zhuangzhuang, additional, Badawi, Mohamed, additional, Ross, Jeremy, additional, Pothacamury, Rajvineeth, additional, Bueno, Orlando, additional, Dobkowska, Edyta, additional, Stadtmauer, Edward, additional, and Costa, Luciano, additional

Published
2023
Full Text
View/download PDF

33. Geriatric Assessment Reveals Actionable Impairments in Hematopoietic Stem Cell Transplantation Candidates Age 18 to 80 Years

Author

Lew, Meagan V., Ren, Yi, Lowder, Yen P., Siamakpour-Reihani, Sharareh, Ramalingam, Sendhilnathan, Romero, Kristi M., Thompson, Jillian C., Bohannon, Lauren M., McIntyre, Jackie, Tang, Helen, Van Opstal, Jolien, Johnson, Ernaya, Cohen, Harvey Jay, Bartlett, David B., Pastva, Amy M., Morey, Miriam, Hall, Katherine S., Smith, Patrick, Peters, Katherine B., Somers, Tamara J., Kelleher, Sarah, Smith, Sophia K., Wischmeyer, Paul E., Lin, Pao-Hwa, Wood, William A., Thorpe, Glynnis, Minor, Kerry, Wiggins, Kristi, Hennig, Therese, Helms, Tanya, Welch, Renee, Matthews, Brittany, Liu, JoAnn, Burleson, Jill, Aberant, Thomas, Engemann, Ashley K., Henshall, Bethany, Darby, Maurisa, Proch, Christina, Dellascio, Michelle, Pittman, Alyssa, Suminguit, Jacob, Choi, Taewoong, Gasparetto, Cristina, Long, Gwynn D., Lopez, Richard D., Sarantopoulos, Stefanie, Horwitz, Mitchell E., Chao, Nelson J., and Sung, Anthony D.

Published
2022
Full Text
View/download PDF

34. Home-Based Hematopoietic Cell Transplantation in the United States

Author

Sung, Anthony D., Giri, Vinay K., Tang, Helen, Nichols, Krista Rowe, Lew, Meagan V., Bohannon, Lauren, Ren, Yi, Jung, Sin-Ho, Dalton, Tara, Bush, Amy, Van Opstal, Jolien, Artica, Alexandra, Messina, Julia, Shelby, Rebecca, Frith, Jennifer, Lassiter, Martha, Burleson, Jill, Leonard, Kari, Potter, Ashley S., Choi, Taewoong, Gasparetto, Cristina J., Horwitz, Mitchell E., Long, Gwynn D., Lopez, Richard D., Sarantopoulos, Stefanie, and Chao, Nelson J.

Published
2022
Full Text
View/download PDF

36. Treatment Outcomes and Health Care Resource Utilization in Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide-only Maintenance, Any Maintenance, or No Maintenance: Results from the Connect MM Registry

Author

Rifkin, Robert M., Jagannath, Sundar, Durie, Brian G.M., Narang, Mohit, Terebelo, Howard R., Gasparetto, Cristina J., Toomey, Kathleen, Hardin, James W., Wagner, Lynne, Parikh, Kejal, Abouzaid, Safiya, Srinivasan, Shankar, Kitali, Amani, Zafar, Faiza, and Abonour, Rafat

Published
2018
Full Text
View/download PDF

38. Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma

Author

Kumar, Shaji, Kaufman, Jonathan L., Gasparetto, Cristina, Mikhael, Joseph, Vij, Ravi, Pegourie, Brigitte, Benboubker, Lofti, Facon, Thierry, Amiot, Martine, Moreau, Philippe, Punnoose, Elizabeth A., Alzate, Stefanie, Dunbar, Martin, Xu, Tu, Agarwal, Suresh K., Enschede, Sari Heitner, Leverson, Joel D., Ross, Jeremy A., Maciag, Paulo C., Verdugo, Maria, and Touzeau, Cyrille

Published
2017
Full Text
View/download PDF

41. Financial Toxicity and Quality of Life in Patients Undergoing Stem-Cell Transplant Evaluation: A Single-Center Analysis

Author

Hussaini, S.M. Qasim, Ren, Yi, Racioppi, Alessandro, Lew, Meagan V., Bohannon, Lauren, Johnson, Ernaya, Li, Yan, Thompson, Jillian C., Henshall, Bethany, Darby, Maurisa, Choi, Taewoong, Lopez, Richard D., Sarantopoulos, Stefanie, Gasparetto, Cristina, Long, Gwynn D., Horwitz, Mitchell E., Chao, Nelson J., Zafar, S. Yousuf, and Sung, Anthony D.

Published
2024
Full Text
View/download PDF

47. Decreased Mortality in 1-Year Survivors of Umbilical Cord Blood Transplant vs. Matched Related or Matched Unrelated Donor Transplant in Patients with Hematologic Malignancies

Author

Bohannon, Lauren, Tang, Helen, Page, Kristin, Ren, Yi, Jung, Sin-Ho, Artica, Alexandra, Britt, Anne, Islam, Prioty, Siamakpour-Reihani, Sharareh, Giri, Vinay, Lew, Meagan, Kelly, Matthew, Choi, Taewoong, Gasparetto, Cristina, Long, Gwynn, Lopez, Richard, Rizzieri, David, Sarantopoulos, Stefanie, Chao, Nelson, Horwitz, Mitchell, and Sung, Anthony

Published
2021
Full Text
View/download PDF

48. Post-Transplant Outcomes in High-Risk Compared with Non–High-Risk Multiple Myeloma: A CIBMTR Analysis

Author

Scott, Emma C., Hari, Parameswaran, Sharma, Manish, Le-Rademacher, Jennifer, Huang, Jiaxing, Vogl, Dan, Abidi, Muneer, Beitinjaneh, Amer, Fung, Henry, Ganguly, Siddhartha, Hildebrandt, Gerhard, Holmberg, Leona, Kalaycio, Matt, Kumar, Shaji, Kyle, Robert, Lazarus, Hillard, Lee, Cindy, Maziarz, Richard T., Meehan, Kenneth, Mikhael, Joseph, Nishihori, Taiga, Ramanathan, Muthalagu, Usmani, Saad, Tay, Jason, Vesole, David, Wirk, Baldeep, Yared, Jean, Savani, Bipin N., Gasparetto, Cristina, Krishnan, Amrita, Mark, Tomer, Nieto, Yago, and D'Souza, Anita

Published
2016
Full Text
View/download PDF

49. Chlorhexidine Gluconate Bathing Reduces the Incidence of Bloodstream Infections in Adults Undergoing Inpatient Hematopoietic Cell Transplantation

Author

Giri, Vinay K., Kegerreis, Kristin G., Ren, Yi, Bohannon, Lauren M., Lobaugh-Jin, Erica, Messina, Julia A., Matthews, Anita, Mowery, Yvonne M., Sito, Elizabeth, Lassiter, Martha, Saullo, Jennifer L., Jung, Sin-Ho, Ma, Li, Greenberg, Morris, Andermann, Tessa M., van den Brink, Marcel R.M., Peled, Jonathan U., Gomes, Antonio L.C., Choi, Taewoong, Gasparetto, Cristina J., Horwitz, Mitchell E., Long, Gwynn D., Lopez, Richard D., Rizzieri, David A., Sarantopoulos, Stefanie, Chao, Nelson J., Allen, Deborah H., and Sung, Anthony D.

Published
2021
Full Text
View/download PDF

50. Assessing the Feasibility of a Novel mHealth App in Hematopoietic Stem Cell Transplant Patients

Author

Racioppi, Alessandro, Dalton, Tara, Ramalingam, Sendhilnathan, Romero, Kristi, Ren, Yi, Bohannon, Lauren, Arellano, Consuelo, Jonassaint, Jude, Miller, Hilary, Barak, Ian, Fish, Laura J., Choi, Taewoong, Gasparetto, Cristina, Long, Gwynn D., Lopez, Richard D., Rizzieri, David A., Sarantopoulos, Stefanie, Horwitz, Mitchell E., Chao, Nelson J., Shah, Nirmish R., and Sung, Anthony D.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results